These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 21327941

  • 1. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
    Jones DT, Mulholland SA, Pearson DM, Malley DS, Openshaw SW, Lambert SR, Liu L, Bäcklund LM, Ichimura K, Collins VP.
    Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
    [Abstract] [Full Text] [Related]

  • 2. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW.
    Cancer; 2012 Jan 15; 118(2):452-60. PubMed ID: 21717448
    [Abstract] [Full Text] [Related]

  • 3. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, Schittenhelm J.
    J Clin Pathol; 2014 Jul 15; 67(7):556-61. PubMed ID: 24607494
    [Abstract] [Full Text] [Related]

  • 4. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X, Wei J, Liu Y, Li P, Fan L, Wang Y, Li M, Zhao D, Yu Z, Ye J, Guo Y, Yan Q, Guo S, Wang Z.
    Sci Rep; 2017 Oct 12; 7(1):13038. PubMed ID: 29026176
    [Abstract] [Full Text] [Related]

  • 5. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, Arslantaş A.
    Gene; 2015 Jan 01; 554(1):81-6. PubMed ID: 25455102
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J, Sharif S, Afsharnezhad S, Lotfi M, Raziee HR, Ghaffarzadegan K, Moradi A, Rahighi S, Behravan J.
    Cancer Invest; 2009 Oct 01; 27(8):825-9. PubMed ID: 19544111
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
    Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM, Dinjens WN.
    J Neurooncol; 2011 Feb 01; 101(3):405-17. PubMed ID: 20593220
    [Abstract] [Full Text] [Related]

  • 10. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas.
    Koos B, Peetz-Dienhart S, Riesmeier B, Frühwald MC, Hasselblatt M.
    Neuropathol Appl Neurobiol; 2010 Jun 01; 36(4):356-8. PubMed ID: 20202118
    [No Abstract] [Full Text] [Related]

  • 11. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
    Shao LW, Pan Y, Qi XL, Li YX, Ma XL, Yi WN, Zhang J, Zhong YF, Chang Q.
    Histol Histopathol; 2016 Jan 01; 31(1):103-14. PubMed ID: 26395639
    [Abstract] [Full Text] [Related]

  • 12. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.
    Acta Neuropathol; 2009 Oct 01; 118(4):469-74. PubMed ID: 19554337
    [Abstract] [Full Text] [Related]

  • 13. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
    Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C.
    Acta Neuropathol; 2010 Aug 01; 120(2):261-7. PubMed ID: 20514489
    [Abstract] [Full Text] [Related]

  • 14. p53 abnormality and tumor invasion in patients with malignant astrocytoma.
    Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S.
    Brain Tumor Pathol; 2010 Oct 01; 27(2):95-101. PubMed ID: 21046311
    [Abstract] [Full Text] [Related]

  • 15. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, Chen CY, Lee H.
    Ann Surg Oncol; 2008 Nov 01; 15(11):3272-7. PubMed ID: 18712569
    [Abstract] [Full Text] [Related]

  • 16. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
    Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K.
    Int J Cancer; 2012 Sep 01; 131(5):1104-13. PubMed ID: 22020830
    [Abstract] [Full Text] [Related]

  • 17. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C.
    Acta Neuropathol; 2009 Sep 01; 118(3):401-5. PubMed ID: 19543740
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M, Peraud A, Leroch B, Kreth FW.
    Cancer; 2004 Sep 01; 101(5):1028-35. PubMed ID: 15329912
    [Abstract] [Full Text] [Related]

  • 19. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2004 Jul 01; 108(1):49-56. PubMed ID: 15118874
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC.
    Clin Cancer Res; 2009 Nov 01; 15(21):6683-93. PubMed ID: 19861461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.